Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.
The median cancer-specific survival was 56.5 months.
The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey.
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.
Investigators presented the longest phase 3 follow-up reported for a checkpoint inhibitor combination therapy in aRCC.
Researchers determined that few patients with poor risk aRCC were receiving first-line avelumab plus axitinib.
Patients with BAP1-mutant ccRCC have very poor prognosis and comprise 10% to 15% of ccRCC cases.
